Pulse Biosciences, Inc.

Equities

PLSE

US74587B1017

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 01:30:00 29/05/2024 am IST			5-day change	1st Jan Change
13.32 ^USD	+17.15%		+36.90%	+8.82%

20/05	Pulse Biosciences Moves New Record Date for Rights Offering	MT
14/05	Pulse Biosciences Appoints Burke Barrett as President, CEO	MT

Pulse Biosciences, Inc. Announces Resignation of Ed Ebbers as Executive Vice President and General Manager of Dermatology

March 22, 2022 at 02:23 am IST

On March 18, 2022, Pulse Biosciences, Inc. and Mr. Ed Ebbers, Executive Vice President and General Manager of Dermatology, agreed that he would resign from the Company, effective as of March 18, 2022.

Latest news about Pulse Biosciences, Inc.

Pulse Biosciences Moves New Record Date for Rights Offering	21/05	MT
Pulse Biosciences Appoints Burke Barrett as President, CEO	15/05	MT
Pulse Biosciences, Inc Announces CEO Changes	15/05	CI
Pulse Biosciences, Inc Announces Executive Changes	15/05	CI
Pulse Biosciences, Inc. Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System	09/05	CI
Transcript : Pulse Biosciences, Inc., Q1 2024 Earnings Call, May 07, 2024	08/05
Pulse Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Sector Update: Health Care Stocks Slide Late Afternoon	02/04	MT
Pulse Biosciences Shares Fall After Q4 Results, Rights Issue Plans	01/04	MT
Transcript : Pulse Biosciences, Inc., Q4 2023 Earnings Call, Mar 28, 2024	29/03
Pulse Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03	CI
Pulse Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/03	CI
Sector Update: Health Care Stocks Ease Late Afternoon	09/03	MT
Pulse Biosciences Gets FDA Clearance For Percutaneous Electrode System	09/03	MT
Pulse Biosciences, Inc. Announces FDA 510(K) Clearance for its CellFX nsPFA Percutaneous Electrode System	08/03	CI
Pulse Biosciences, Inc. Announces Positive 60-Day Follow-Up Evaluations for Initial Patients Treated in the Cellfx Nspfa 360° Cardiac Catheter First-In-Human Feasibility Study	14/02	CI
Sector Update: Health Care Stocks Decline Pre-Bell Tuesday	02/01	MT
Pulse Biosciences Files FDA Notification to Advance Testing of New Cardiac Clamp	02/01	MT
Pulse Biosciences Files 510(K) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp	02/01	CI
Pulse Biosciences, Inc. Announces First-In-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation Cardiac Catheter	20/12	CI
Pulse Biosciences Insider Bought Shares Worth $843,504, According to a Recent SEC Filing	14/12	MT
Pulse Biosciences Insider Bought Shares Worth $1,117,085, According to a Recent SEC Filing	01/12	MT
Pulse Biosciences Up 16% on Product Updates, Potential Stock Purchases by Duggan	28/11	DJ
Pulse Biosciences Cleared to Start Catheter Ablation Feasibility Trial; Set to File Application for Cardiac Clamp; Shares Rise	28/11	MT
Sector Update: Health Care Stocks Rise Tuesday Afternoon	22/11	MT

Chart Pulse Biosciences, Inc.

Duration

Period

More charts

Company Profile

Pulse Biosciences, Inc. is a bioelectric medicine company. The Companyâs proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Companyâs Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.

Sector

Advanced Medical Equipment & Technology

Calendar

06/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

	1st Jan change	Capi.
PULSE BIOSCIENCES, INC.	+8.82%	63Cr
THERMO FISHER SCIENTIFIC	+7.87%	22TCr
DANAHER CORPORATION	+11.83%	19TCr
INTUITIVE SURGICAL, INC.	+18.87%	14TCr
BOSTON SCIENTIFIC CORPORATION	+30.03%	11TCr
SIEMENS HEALTHINEERS AG	+2.32%	6.52TCr
EDWARDS LIFESCIENCES CORPORATION	+14.15%	5.3TCr
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+2.68%	5.03TCr
AGILENT TECHNOLOGIES, INC.	+6.60%	4.42TCr
GE HEALTHCARE TECHNOLOGIES INC.	+1.85%	3.64TCr

Other Advanced Medical Equipment & Technology